Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > My investment

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Jun 08, 2021 8:26am

209 Views

Post# 33346413

RE:My investment

In the same boat and down 24% / decent chunk of change but I have come to the conclusion that these are knowns:

Clear need for the product TAM is massive
By combining H2S on known / highly studied drugs i.e. nonsteroidal anti-inflammatory drugs (NSAIDs) the odds of a successful PH3 is increased
Science has been tested with a very successful ph2 / backed by Wallace's decades of research
Platform play is taking shape and 352 human studies are coming at a good time (yes mgmt likely stalled too much on brining more than one shot to target sooner but we are where we are)
CMO is a rock star and knows the FDA / how to create a successful PH3
Dosing data is likely going to show a very minimum dosage which will also increase probability of PH3 passing
More partnerships are coming as the value prop is massive for BPs
PH3 will start this year and NASDAQ will happen which will be stage gates / increase institutional investor base

I decided a year + ago that I'd see this out, the upside is too much if PH3 pans out. Venting is nature but the juice will be worth the squeeze in the end